Paramagnetic contrast enhancement in MRI imaging of liver using an original hepatotropic high-affinity agent GDOF-Mn-DTPA

Background. The use of modern hepatotropic contrast compounds is associated with the risk of side-effects, like accumulation of metal ions in tissues and the development of systemic pathological reactions. Therefore, currently, obtaining of high-affinity hepatotropic drugs is under investigation.
Objective. There was studied the dependence of specific contrast properties of the paramagnetic complex 2-(2-carboxymethyl-(4-hexa-decyloxyphenyl-carbamoyl-methyl))-aminoethyl-(4-hexadecyl-oxyphenylcarbamoyl methyl)-aminoacetic acid with manganese — GDOF-Mn-DTPA — in magnetic resonance imaging from the administered dose of the drug.
Design and methods. The dynamics of changes in the liver contrast ratio over time at different dosages of the contrast compound GDOF-Mn-DTPA was evaluated, and changes in the T1 relaxation time of liver and kidney tissue of laboratory animals (Wistar rats, more than 300 g) at different dosages of GDOF-Mn-DTPA were calculated.
Results. Visual analysis of contrast-enhanced MRI scans with GDOF-Mn-DTPA already at a dose of 0.025 mmol/kg reliably visualized the accumulation of paramagnet in the liver, while further concentration of the drug in the bile ducts of animals was noted, with the actual absence of visually detectable kidney contrast. When evaluating the T1 relaxation time for the liver and kidneys, a persistent decrease in the T1 time for liver tissue was obtained for doses of 0.1, 0.05 and 0.025 mmol/kg, in particular for 0.025 mmol/kg from the initial 760 (747–755) MS to 488 (474–505) MS (p < 0.02). On the contrary, the obtained values of T1 relaxation time for kidney tissue showed no significant accumulation of the paramagnetic contrast compound GDOF-Mn-DTPA to the renal parenchyma at a dosage of 0.025 mmol / kg or lower. GDOF-Mn-DTPA showed a high degree of hepatoselectivity, with a pronounced reduced excretion through the kidneys.
Conclusion. The GDOF-Mn-DTPA complex is a stable compound with a high degree of selective contrast of the hepatic parenchyma, with minimal or no renal excretion, a reliable basis for a hepatoselective contrast agent for imaging and functional studies of the liver with MRI and clinical use in the near future.

1. Antonenkova NN, Averkin YuI, Belozerkovskii I.B. Oncology^ Guidebook for physicians. Minsk. 2007. 703P.

2. Shimanovskii NL Contrast agents: Guidebook on rational use. Moscow., GEOTAR-Media. 2006. 464 P.

3. Vdovenko VS., Karelskaya NA., Kondratyev EV., Galchina YS., Ionkin DA., Chzhao AV., Revishvili AS., Karmazanovsky GG Vdovenko V.S Сryodestruсtion of mаlignаnt liver lesions: MRI monitoring of treаtment, preliminаry results. Medical Visualization. 2019; 23 (1): 8–18. DOI: 10.24835/1607-0763-2019-1-8-18

4. Voskanyan SE, Bashkov AN, Karmazanovsky GG, Naydenov EV, Ionova EA. Planning principles for radial surgical interventions for liver alveococckosis based on computer and magnetic resonance imaging. Annals of surgical hepatology2020; 25(2): 100-112. DOI: 10.16931/1995-5464.20202100-112 .

5. Borodin OYu, Belyanin ML, Semichev EB, Filimonov VD. Pre-clinical analysis of contrast-enhanced angiography with Gd- and Mn-based paramagnetic contrast agents. Radiologic diagnostic and therapy. 2011; (3): 43 - 53.

6. Borodin OYu, Semichev EB, Dambaev GTs. Analysis of contras properties in dynamic magnetic resonance tomography with lipophylic contrast agent GDOF-Mn-DTPA in rats after hepatic surgery with classic hepatic suture. Russian Electronic Journal of Radiology. 2012; 2(2): 86–87.

7. Sannikov M.Y., Borodin O.Y., Beljanin M.L., Semichev E.V., Bushlanov P.S., Filimonov V.D., Ussov W.Y.Preclinical evaluation of GDOF-Mn-DTPA as contrast media versus Gd-EOB-DTPA for contrast-enhanced magnetic resonance imaging. Proceedings of higher educational institutions. Physics. 2015; 58(12-2): 79-84.

8. Pettersson H, Slone RM, Spanier S, Gillespie Th, Fitzsimmons JR, Scott KN. Musculoskeletal Tumors: T1 and T2 Relaxation Times Measurement Using Conventional 1,5T Scanner. Radiology. 1988;(167): 783 – 785.

9. Pan D, Schmieder AH, Wickline SA, Lanza GM. Manganese-based MRI contrast agents: past, present and future. Tetrahedron. 2011; 67(44): 8431 - 8444. doi: 10.1016/j.tet.2011.07.076.

10. Ussov WYu, Belyanin ML, Borodin OYu, Filimonov VD. Use of Mn-DTPA for paramagnetic contrast enhancement in MRI: results of pre-clinical studies and compariton to Gd-DTPA. Medical Visualization. 2007; 11(4): 132–142.

11. Churin AA, Karpova GV, Fomina TI, Belyanin VL, Ussov WYu. Pre-clinical toxicologic evaluation of pentamang and mangascan. Experimental and clinical pharmacology. 2008; 71(4): 49–52.

12. Barandov A, Bartelle BB, Williamson CG, Loucks ES, Lippard SJ, Jasanoff A. Sensing intracellular calcium ions using a manganese-based MRI contrast agent. Nat Commun. 2019; 10(1): 897. doi: 10.1038/s41467-019-08558-7.

13. Venter A, Szulc DA, Loai S, Ganesh T, Haedicke IE, Cheng HL. A manganese porphyrin-based T1 contrast agent for cellular MR imaging of human embryonic stem cells. Sci Rep. 2018; 8(1): 12129. doi: 10.1038/s41598-018-30661-w.

14. Jørgensen JT, Rief M, Brismar TB. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects. Acta radiologica. 2012; 53: 707-713.

15. Ussov W.Yu., Filimonov V.D., Belyanin M.L., Bezlepkin A.I., Lucic M.A., Kovalenko A.Yu., Rogovskaya Yu.V., Shimanovskiy N.L. Synthesis, quantum chemistry analysis and pre-clinical in vivo evalution of magnetic resonance imaging abilities of paramagnetic manganese complex with 2,3-dimercaptosuccinate (succimang). Medical Visualization. 2019;(3):133-143. (In Russ.) https://doi.org/10.24835/1607-0763-2019-3-133-143

16. Islam MK, Kim S, Kim HK. Manganese complex of ethylenediaminetetraacetic acid (EDTA)− benzothiazole aniline (BTA) conjugate as a potential liver-targeting MRI contrast agent. Journal of medicinal chemistry. 2017. 60: 2993-3001.